NPS isovaleramide migraine study
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
NPS' alifatic amide neuromodulator isovaleramide (NPS 1776) fails to show significance in a proof-of-concept study in moderate to severe migraine "due to a higher than expected placebo response," NPS says Oct. 11. A positive response was seen in 60% of patients receiving a high dose (800 mg), 64% receiving a low dose (400 mg), and 56% of placebo patients in the 189-patient Phase IIa trial. NPS "will complete its evaluation of data from this study, and plans to continue to explore the development of NPS 1776 in other indications." Other potential indications for isovaleramide include bipolar disorder and epilepsy...
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.